自身免疫性肝病与肠道微生物发生发展及预后的关系
Relationship between Gut Microbiota and Development and Prognosis of Autoimmune Liver Disease
摘要: 自身免疫性肝病(Autoimmune liver disease, AILD)是一组免疫介导的肝病，主要包括自身免疫性肝炎(Autoimmune hepatitis, AIH)、原发性胆汁性胆管炎(Primary biliary cholangitis, PBC)和原发性硬化性胆管炎(Primary sclerosing cholangitis, PSC)。AILD目前其发病机制尚不明确，大多数学者认为可能是遗传、免疫、环境等多个因素共同参与的结果。随着近几年微生物研究越来越受到学者重视，不少研究发现肠道微生物与自身免疫性肝病关系越来越密切。本文综述AILD和肠道微生物之间的关系，总结AILD中微生物的组成和功能改变，讨论肠道微生物在疾病发生和进展中的潜在作用，并为AILD的治疗方法提供新的方向。
Abstract: Autoimmune liver disease (AILD) is a group of immune mediated liver diseases, mainly including Autoimmune hepatitis (AIH), Primary biliary cholangitis (PBC) and Primary sclerosing cholangitis (PSC). At present, the pathogenesis of autoimmune liver disease is not clear, and most scholars be-lieve that it may be the result of the joint participation of genetic, immune, environmental and other factors. In recent years, more and more scholars pay attention to microbial research. Many studies have found the relationship between intestinal microorganisms and autoimmune liver disease. This article summarizes the composition and functional changes of Gut microbiota, dis-cusses the potential role of Gut microbiota in disease occurrence and progression, and provides a new direction for the treatment of AILD.
文章引用：李玉杰, 刘丹平. 自身免疫性肝病与肠道微生物发生发展及预后的关系[J]. 临床医学进展, 2022, 12(11): 10814-10821. https://doi.org/10.12677/ACM.2022.12111557

参考文献

[1] Schwenger, K.J., Clermont-Dejean, N. and Allard, J.P. (2019) The Role of the Gut Microbiome in Chronic Liver Disease: The Clinical Evidence Revised. JHEP Reports, 1, 214-226. [Google Scholar] [CrossRef] [PubMed]
[2] Miura, K. and Ohnishi, H. (2014) Role of Gut Microbiota and Toll-Like Receptors in Nonalcoholic Fatty Liver Disease. World Journal of Gastroenterology, 20, 7381-7391. [Google Scholar] [CrossRef] [PubMed]
[3] Rinninella, E., Raoul, P., Cintoni, M., et al. (2019) What Is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms, 7, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[4] Tilg, H., Adolph, T.E. and Trauner, M. (2022) Gut-Liver Axis: Pathophysiological Concepts and Clinical Implications. Cell Metabolism, 34, 1700-1718. [Google Scholar] [CrossRef] [PubMed]
[5] Mack, C.L., Adams, D., Assis, D.N., et al. (2020) Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases. Hepatology, 72, 671-722. [Google Scholar] [CrossRef] [PubMed]
[6] Saccucci, M., Di Carlo, G., Bossu, M., et al. (2018) Autoimmune Diseases and Their Manifestations on Oral Cavity: Diagnosis and Clinical Management. Journal of Immunology Research, 2018, Article ID: 6061825. [Google Scholar] [CrossRef] [PubMed]
[7] Wei, Y., Li, Y., Yan, L., et al. (2020) Alterations of Gut Microbiome in Autoimmune Hepatitis. Gut, 69, 569-577. [Google Scholar] [CrossRef] [PubMed]
[8] Liwinski, T., Casar, C., Ruehlemann, M.C., et al. (2020) A Dis-ease-Specific Decline of the Relative Abundance of Bifidobacterium in Patients with Autoimmune Hepatitis. Alimentary Pharmacology & Therapeutics, 51, 1417-1428. [Google Scholar] [CrossRef] [PubMed]
[9] Elsherbiny, N.M., Rammadan, M., Hassan, E.A., et al. (2020) Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients. Microorganisms, 8, Article No. 1011. [Google Scholar] [CrossRef] [PubMed]
[10] Ma, L., et al. (2021) Fecal Microbiota Transplantation Controls Progression of Experimental Autoimmune Hepatitis in Mice by Modulating the TFR/TFH Immune Imbalance and Intestinal Microbiota Composition. Frontiers in Immunology, 12, Article ID: 728723. [Google Scholar] [CrossRef] [PubMed]
[11] Liu, Q., Tian, H., Kang, Y., et al. (2021) Probiotics Alleviate Autoimmune Hepatitis in Mice through Modulation of Gut Microbiota and Intestinal Permeability. The Journal of Nu-tritional Biochemistry, 98, Article ID: 108863. [Google Scholar] [CrossRef] [PubMed]
[12] Zhang, H., Liu, M., Liu, X., et al. (2020) Bifidobacterium animalis ssp. Lactis 420 Mitigates Autoimmune Hepatitis through Regulating Intestinal Barrier and Liver Immune Cells. Frontiers in Immunology, 11, Article ID: 569104. [Google Scholar] [CrossRef] [PubMed]
[13] Dyson, J.K., Beuers, U., Jones, D.E.J., et al. (2018) Primary Sclerosing Cholangitis. The Lancet, 391, 2547-2559. [Google Scholar] [CrossRef] 
[14] Lin, R., Zhou, L., Zhang, J., et al. (2015) Abnormal Intestinal Permeability and Microbiota in Patients with Autoimmune Hepatitis. International Journal of Clinical and Experimental Pathology, 8, 5153-5160.
[15] Lou, J., Jiang, Y., Rao, B., et al. (2020) Fecal Microbiomes Distinguish Patients with Autoimmune Hepatitis from Healthy Individuals. Frontiers in Cellular and Infection Microbiology, 10, Article No. 342. [Google Scholar] [CrossRef] [PubMed]
[16] Guo, S., Nighot, M., Al-Sadi, R., et al. (2015) Lipopolysaccharide Regulation of Intestinal Tight Junction Permeability Is Mediated by TLR4 Signal Transduction Pathway Activation of FAK and MyD88. The Journal of Immunology, 195, 4999-5010. [Google Scholar] [CrossRef] [PubMed]
[17] Kim, M.H., Kang, S.G., Park, J.H., et al. (2013) Short-Chain Fatty Acids Activate GPR41 and GPR43 on Intestinal Epithelial Cells to Promote Inflammatory Responses in Mice. Gastroenterology, 145, 396-406e1-10. [Google Scholar] [CrossRef] [PubMed]
[18] Liu, C., Wang, Y.L., Yang, Y.Y., et al. (2021) Novel Ap-proaches to Intervene Gut Microbiota in the Treatment of Chronic Liver Diseases. FASEB Journal, 35, e21871. [Google Scholar] [CrossRef] 
[19] Ma, L., Zhang, L., Zhuang, Y., et al. (2022) Lactobacillus Improves the Effects of Prednisone on Autoimmune Hepatitis via Gut Microbiota-Mediated Follicular Helper T Cells. Cell Communication and Signaling, 20, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[20] Yamaguchi, A., Teratani, T., Chu, P.S., et al. (2021) Hepatic Adenosine Triphosphate Reduction through the Short-Chain Fatty Acids-Peroxisome Proliferator-Activated Receptor gamma-Uncoupling Protein 2 Axis Alleviates Immune-Mediated Acute Hepatitis in Inulin-Supplemented Mice. Hepatology Communications, 5, 1555-1570. [Google Scholar] [CrossRef] [PubMed]
[21] Karlsen, T.H., Folseraas, T., Thorburn, D., et al. (2017) Primary Sclerosing Cholangitis—A Comprehensive Review. Journal of Hepatology, 67, 1298-1323. [Google Scholar] [CrossRef] [PubMed]
[22] Sabino, J., Vieira-Silva, S., Machiels, K., et al. (2016) Primary Sclerosing Cholangitis Is Characterised by Intestinal Dysbiosis Independent from IBD. Gut, 65, 1681-1689. [Google Scholar] [CrossRef] [PubMed]
[23] Jansen, P.L., Ghallab, A., Vartak, N., et al. (2017) The Ascending Pathophysiology of Cholestatic Liver Disease. Hepatology, 65, 722-738. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, H.X., Keane, R., Sheng, L., et al. (2015) Implications of Microbiota and Bile Acid in Liver Injury and Regeneration. Journal of Hepatology, 63, 1502-1510. [Google Scholar] [CrossRef] [PubMed]
[25] Bleier, J.I., Katz, S.C., Chaudhry, U.I., et al. (2006) Biliary Ob-struction Selectively Expands and Activates Liver Myeloid Dendritic Cells. The Journal of Immunology, 176, 7189-7195. [Google Scholar] [CrossRef] [PubMed]
[26] Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., et al. (2004) Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis. Cell, 118, 229-241. [Google Scholar] [CrossRef] [PubMed]
[27] Fukui, H. (2019) Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases, 7, Article No. 58. [Google Scholar] [CrossRef] [PubMed]
[28] Nakamoto, N., Sasaki, N., Aoki, R., et al. (2019) Gut Pathobionts Underlie Intestinal Barrier Dysfunction and Liver T Helper 17 Cell Immune Response in Primary Sclerosing Cholangitis. Nature Microbiology, 4, 492-503. [Google Scholar] [CrossRef] [PubMed]
[29] Bajer, L., Kverka, M., Kostovcik, M., et al. (2017) Distinct Gut Microbiota Profiles in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis. World Journal of Gastro-enterology, 23, 4548-4558. [Google Scholar] [CrossRef] [PubMed]
[30] Lv, L.X., Fang, D.Q., Shi, D., et al. (2016) Alterations and Corre-lations of the Gut Microbiome, Metabolism and Immunity in Patients with Primary Biliary Cirrhosis. Environmental Microbiology, 18, 2272-2286. [Google Scholar] [CrossRef] [PubMed]
[31] Tang, R., Wei, Y., Li, Y., et al. (2018) Gut Microbial Profile Is Altered in Primary Biliary Cholangitis and Partially Restored after UDCA Therapy. Gut, 67, 534-541. [Google Scholar] [CrossRef] [PubMed]
[32] Suri, J., Patwardhan, V. and Bonder, A. (2019) Pharmacologic Management of Primary Sclerosing Cholangitis: What’s in the Pipeline? Expert Review of Gastroenterology & Hepatology, 13, 723-729. [Google Scholar] [CrossRef] [PubMed]
[33] Cremers, C.M., Knoefler, D., Vitvitsky, V., et al. (2014) Bile Salts Act as Effective Protein-Unfolding Agents and Instigators of Disulfide Stress in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 111, E1610-E1619. [Google Scholar] [CrossRef] [PubMed]
[34] D’aldebert, E., Biyeyeme Bi Mve, M.J., Mergey, M., et al. (2009) Bile Salts Control the Antimicrobial Peptide Cathelicidin through Nuclear Receptors in the Human Biliary Epithelium. Gastroenterology, 136, 1435-1443. [Google Scholar] [CrossRef] [PubMed]
[35] Devkota, S. and Chang, E.B. (2015) Interactions between Diet, Bile Acid Metabolism, Gut Microbiota, and Inflammatory Bowel Diseases. Digital Distribution, 33, 351-356. [Google Scholar] [CrossRef] [PubMed]
[36] Gahan, C.G. and Hill, C. (2014) Listeria Monocytogenes: Survival and Adaptation in the Gastrointestinal Tract. Frontiers in Cellular and Infection Microbiology, 4, Article No. 9. [Google Scholar] [CrossRef] [PubMed]
[37] Ridlon, J.M., Kang, D.J., Hylemon, P.B., et al. (2014) Bile Acids and the Gut Microbiome. Current Opinion in Gastroenterology, 30, 332-338. [Google Scholar] [CrossRef] 
[38] Kisiela, M., Skarka, A., Ebert, B., et al. (2012) Hydroxysteroid Dehydrogenases (HSDs) in Bacteria: A Bioinformatic Perspective. The Journal of Steroid Biochemistry and Molecular Biology, 129, 31-46. [Google Scholar] [CrossRef] [PubMed]
[39] Sayin, S.I., Wahlstrom, A., Felin, J., et al. (2013) Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-Beta-Muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metabolism, 17, 225-235. [Google Scholar] [CrossRef] [PubMed]
[40] Quinn, R.A., Melnik, A.V., Vrbanac, A., et al. (2020) Global Chemical Effects of the Microbiome Include New Bile-Acid Conjugations. Nature, 579, 123-129. [Google Scholar] [CrossRef] [PubMed]
[41] Assis, D.N., Abdelghany, O., Cai, S.Y., et al. (2017) Combina-tion Therapy of All-Trans Retinoic Acid with Ursodeoxycholic Acid in Patients with Primary Sclerosing Cholangitis: A Human Pilot Study. Journal of Clinical Gastroenterology, 51, e11-e16. [Google Scholar] [CrossRef] 
[42] Watanabe, M., Fukiya, S. and Yokota, A. (2017) Com-prehensive Evaluation of the Bactericidal Activities of Free Bile Acids in the Large Intestine of Humans and Rodents. Journal of Lipid Research, 58, 1143-1152. [Google Scholar] [CrossRef] 
[43] Mattner, J., Savage, P.B., Leung, P., et al. (2008) Liver Autoimmunity Triggered by Microbial Activation of Natural Killer T Cells. Cell Host & Microbe, 3, 304-315. [Google Scholar] [CrossRef] [PubMed]
[44] Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., et al. (2019) The Challenges of Primary Biliary Cholangitis: What Is New and What Needs to Be Done. Journal of Au-toimmunity, 105, Article ID: 102328. [Google Scholar] [CrossRef] [PubMed]
[45] Li, Y., Tang, R., Leung, P.S.C., et al. (2017) Bile Acids and In-testinal Microbiota in Autoimmune Cholestatic Liver Diseases. Autoimmunity Reviews, 16, 885-896. [Google Scholar] [CrossRef] [PubMed]
[46] Terziroli Beretta-Piccoli, B., Mieli-Vergani, G. and Vergani, D. (2022) HLA, Gut Microbiome and Hepatic Autoimmunity. Frontiers in Immunology, 13, Article ID: 980768. [Google Scholar] [CrossRef] [PubMed]

为你推荐